Home›Clinical trials›A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes

A study testing whether a study medicine from Antag Therapeutics, AT673 low dose, can help people lower blood sugar and lose weight.

Recruiting now. Registry record last updated July 24, 2026.

Who can join
Adults 18+, have type 2 diabetes, BMI 27+.
What you take
AT673 low dose, given as part of the study. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The study runs about 9 months.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
Phase Phase 2Sponsor Antag TherapeuticsDrug AT673 low doseClass OtherSites 8 USEnrollment target 150

What this study is for

Primary condition: Adults With Overweight/Obesity and Type 2 Diabetes.

Full scientific study title: A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have type 2 diabetes, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Signed informed consent prior to start the Screening Visit procedures.
  • Female and male participants ≥18 years of age at time of consent
  • BMI g ≥27.0 kg/m2 at screening.
  • HbA1c ≥7 and ≤10% (53-86 mmol/mol) at screening.
  • Diagnosis of type 2 diabetes mellitus for ≥ 180 days prior to screening.

Key exclusion criteria

  • Participant has had gastric bypass or other bariatric surgery or endoscopic procedure or any metabolic procedures (e.g. duodenal resurfacing, intragastric balloon, etc.) except for the following:
  • Liposuction and/or abdominoplasty that was performed \> 1 year before screening
  • Laparoscopic gastric band that was removed \> 1 year before screening
  • Intragastric balloon that was removed \> 1 year before screening
  • Duodenal-jejunal bypass sleeve that was removed \> 1 year before screening.

Where this trial is enrolling

This trial has 8 sites across 5 states. Contact a site coordinator directly to start screening.

Arizona1 site
California1 site
Florida2 sites
Georgia3 sites
Utah1 site
  • CenExel SLC
    Salt Lake City, Utah
    Jenny Hunt Recruitment Manager801-261-2000j.hunt@cenexel.com

Timeline

Started enrolling: June 19, 2026. Expected completion: March 2027. Last updated on ClinicalTrials.gov: July 24, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked July 27, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.